Elixir competitors

Mark L. Baum is the founder and CEO of Imprimis Pharmaceuticals whose mission is to provide patients and physicians with innovative and affordable ophthalmic drugs in the ocular surgery, glaucoma, and dry eye disease markets. He is also a founder and board member of Eton Pharmaceuticals and Surface Pharmaceuticals, as well as a board member and chairman of the audit committee of Ideal Power. He was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region. Prior to Imprimis, as the founder of TBLF, LLC, a private investment fund, He made more than 200 investments into more than 40 private and public companies. In 1999, He founded YesRx, an HIV-focused pharmacy business. He's advocacy for drug pricing and accessibility issues has been reflected as an Op-Ed contributor for the Wall Street Journal and through appearances on CBS, CNN, MSNBC, Fox Business, Bloomberg and Al Jazeera. He is a 1995 cum laude graduate of The University of Texas at Arlington and a 1997 graduate of California Western School of Law.

William Korslin is a Chief Executive Officer at CCS Medical and is based in Harvard, Illinois. He works or has worked as CEO at Centrad Healthcare LLC.

Mark Huetten is a Chief Executive Officer at Navitus Health Solutions LLC and is based in Fort Myers, Florida. He has worked as Director of Rebate Contracting at ARGUS HEALTH SYSTEMS INC, Clinical Pharmacist at Touchpoint Health Plan, and Director of Formulary Management at Navitus Health Solutions LLC. Mark attended University of Wisconsin-Madison between 1982 and 1988.